Literature DB >> 6096286

Bisantrene solubility and skin toxicity studies: efficacy of sodium bicarbonate as a local ulceration antidote.

R T Dorr, Y M Peng, D S Alberts.   

Abstract

Bisantrene solubility and skin toxicity were studied in mice given intraperitoneal (IP) and intradermal (ID) drug respectively. Bisantrene (1 mg/ml) in 5% dextrose readily precipitated in the mouse peritoneum. The admixture of bisantrene into various lipophilic solvents did not reduce drug precipitation in vivo in the mouse or in vitro in human plasma at 37 degrees C. Drug stability studies using high performance liquid chromatography (HPLC) showed markedly reduced bisantrene stability at alkaline pH. Bisantrene skin toxicity in BALB/c mice was characterized by ulceration which persisted for up to four months after ID injection. Skin toxicity was consistently reduced by dilute sodium bicarbonate injection into the bisantrene extravasation site. Three clinical extravasation cases treated with sodium bicarbonate showed no bisantrene ulceration. Ineffective local antidotes included sodium cromolyn, N-acetylcysteine, hydrocortisone, and heat (which appeared to increase toxicity).

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6096286     DOI: 10.1007/bf00171585

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  9 in total

1.  Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man.

Authors:  E J Freireich; E A Gehan; D P Rall; L H Schmidt; H E Skipper
Journal:  Cancer Chemother Rep       Date:  1966-05

2.  High performance liquid chromatography of a new anticancer drug, ADCA--physicochemical properties and pharmacokinetics.

Authors:  Y M Peng; T P Davis; D S Alberts
Journal:  Life Sci       Date:  1981-07-27       Impact factor: 5.037

3.  Experimental model of doxorubicin extravasation in the mouse.

Authors:  R T Dorr; D S Alberts; H S Chen
Journal:  J Pharmacol Methods       Date:  1980-11

4.  Disposition of bisantrene in humans and rabbits: evidence for intravascular deposition of drug as a cause of phlebitis.

Authors:  G Powis; J S Kovach
Journal:  Cancer Res       Date:  1983-02       Impact factor: 12.701

5.  Phase I clinical trial of 9,10-anthracene dicarboxaldehyde (Bisantrene) administered in a five-day schedule.

Authors:  R J Spiegel; R H Blum; M Levin; C A Pinto; J C Wernz; J L Speyer; K S Hoffman; F M Muggia
Journal:  Cancer Res       Date:  1982-01       Impact factor: 12.701

6.  The limited role of corticosteroids in ameliorating experimental doxorubicin skin toxicity in the mouse.

Authors:  R T Dorr; D S Alberts; H S Chen
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

7.  Activity of 9-10 anthracenedicarboxaldehyde bis[(4,5-dihydro-1 H-imidazol-2-yl)hydrazone]dihydrochloride (CL216,942) in a human tumor cloning system. Leads for phase II trials in man.

Authors:  D D Von Hoff; C A Coltman; B Forseth
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

8.  Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride with correlative in vitro human tumor clonogenic assay.

Authors:  D S Alberts; C Mackel; R Pocelinko; S E Salmon
Journal:  Cancer Res       Date:  1982-03       Impact factor: 12.701

9.  Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1 H-imidazol-2-yl)hydrazone] dihydrochloride (CL216,942).

Authors:  D D Von Hoff; J W Myers; J Kuhn; J F Sandbach; R Pocelinko; G Clark; C A Coltman
Journal:  Cancer Res       Date:  1981-08       Impact factor: 12.701

  9 in total
  2 in total

Review 1.  Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays. II. Assay methods, adriamycin and the other antitumour antibiotics.

Authors:  A G Bosanquet
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

2.  Lack of experimental vesicant activity for the anticancer agents cisplatin, melphalan, and mitoxantrone.

Authors:  R T Dorr; D S Alberts; M Soble
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.